OCD: Perspectives on the Next Millennium From the Adult OCD Research Unit, NIMH Intramural Research Program

CNS Spectrums

Volumn 3, Issue S1, 1998, Pages 19-20

  Murphy, Dennis L ^a   Corá Locatelli, Gabriela ^b   Greenberg, Benjamin D ^b  

^a Dr Murphy is chief of the Laboratory of Clinical Science (LCS)   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0006352634     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S109285290000715X     Document Type: Article

References (13)

1. Greenberg, BD, George, MS, Benjamin, J, et al. Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a preliminary study. Am J Psychiatry. 1997; 154: 867–869.
2. Corá-Locatelli, G, Greenberg, BD, Martin, JD, Murphy, DL. Valproate monotherapy in SRI-intolerant OCD patient. Clin Psychiatry. 1998; 59: 82.
3. Corá-Locatelli, G, Greenberg, BD, Martin, JD, Murphy, DL. Rebound psychiatric and physical symptoms after gabapentin discontinuation. J Clin Psychiatry. In press.
4. Corá-Locatelli, G, Greenberg, BD, Martin, J, Leong, Y-M, Murphy, DL. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder Submitted.
5. Broocks, A, Pigott, TA, Hill, JL, et al. Acute administration of ondansetron and m-cpp, alone and in combination, in patients with obsessive-compulsive disorder (OCD) and controls: behavioral and biological results. Psychiatry Research. In press.
6. Broocks, A, Briggs, NC, Pigott, TA, et al. Behavioral, physiological, and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment. Psychopharmacology. 1997; 130: 91–103.
7. Altemus, M, Glowa, JR, Galliven, E, Leong, YM, Murphy, DL. Effects of serotonergic agents on food-restriction-induced hyperactivity. Pharmacol Biochem Behav. 1996; 53: 123–131.
8. Altemus, M, Murphy, DL. Animal models of obsessive-compulsive disorder. In: Westenberg, HGM, Murphy, DL, Den Boer, JA, eds. Advances in the Neurobiology of Anxiety Disorder. New York: Wiley, 1996: 249–278.
9. Bengel, D, Murphy, DL, Andrews, AM, et al. Altered brain serotonin (5-HT) homeostasis and locomotor insensitivity to MDMA (“ecstasy”) in 5-HT transporter-deficient mice. Molecular Pharm. 1998; 53: 649–655.
10. Murphy, DL, Greenberg, B, Altemus, M, Benjamin, J, Grady, T, Pigott, T. The neuropharmacology and neurobiology of obsessive-compulsive disorder: an update on the serotonin hypothesis. In: Westenberg, HGM, Murphy, DL, Den Boer, JA, eds. Advances in Neurobiology of Anxiety. 1996; 2: 279–298.
11. Murphy, DL, Andrews, AM, Wichems, CH, Li, Q, Greenberg, B. Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. J Clin Psychiatry. In press.
12. Weiger, WA. Serotonergic modulation of behaviour: a phylogenetic overview. Biol Rev. 1996; 72: 61–95.
13. Karayiorgou, M, Altemus, M, Galke, BL, et al. Genotype determining low catechol-o-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci USA. 1997; 94: 4572–4575.